Dmitry Balyasny’s Madrigal Pharmaceuticals MDGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$42.4M Buy
+79,011
New +$40.5M 0.05% 416
2025
Q4
Sell
-82,401
Closed -$42.1M 3367
2025
Q3
$37.8M Buy
82,401
+47,901
+139% +$17.9M 0.05% 461
2025
Q2
$10.4M Buy
34,500
+7,285
+27% +$2.17M 0.02% 950
2025
Q1
$9.01M Buy
27,215
+12,987
+91% +$4.27M 0.01% 971
2024
Q4
$4.39M Buy
+14,228
New +$4M 0.01% 1344
2024
Q3
Sell
-2,448
Closed -$626K 2995
2024
Q2
$686K Buy
+2,448
New +$583K ﹤0.01% 1939
2023
Q4
Sell
-28,204
Closed -$4.12M 2734
2023
Q3
$4.12M Buy
+28,204
New +$5.31M 0.01% 1166
2023
Q1
Sell
-200
Closed -$58K 2956
2022
Q4
$58K Buy
+200
New +$19.6K ﹤0.01% 2328

Other funds holding MDGL

Dmitry Balyasny's MDGL Position: Q2 2026 in Review

Dmitry Balyasny opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 79,011 shares worth $42.4M. The stake represents 0.05% of the portfolio and ranks #416 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in MDGL as recently as Q3 2025.

Dmitry Balyasny first reported a position in MDGL in Q4 2022 and has held it in 8 quarters since. 411 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Dmitry Balyasny held 79,011 shares of Madrigal Pharmaceuticals worth $42.4M as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Dmitry Balyasny position in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.05% of Dmitry Balyasny's portfolio in Q2 2026, its #416 holding.
  • Dmitry Balyasny first reported a position in Madrigal Pharmaceuticals in Q4 2022 and has held it in 8 quarters since.
  • 411 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.